GI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 Inhibitors
A large cohort study found three popular GLP-1-based diabetes drugs — semaglutide, dulaglutide, and tirzepatide — carry similar risks for serious adverse GI events, with a rate of about 12…